This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: clopidogrel

News from the 59th Annual Scientific Session of the American College of Cardiology

May 2010 Br J Cardiol 2010;17:111-5

News from the 59th Annual Scientific Session of the American College of Cardiology

BJ Cardio Staff

Abstract

ACCORD/INVEST: do not aim for normal blood pressure in diabetes patients with CAD The results of two trials comparing intensive versus more conventional blood pressure lowering in patients with diabetes at high cardiovascular risk have suggested that intensive treatment is not necessary and may be harmful in this population. In the ACCORD BP (Action to Control Cardiovascular Risk in Diabetes – Blood Pressure) trial, while intensive blood pressure treatment did reduce the risk of stroke, it failed to reduce the overall risk of cardiovascular events in patients and was associated with an increase in adverse events due to antihypertensive ther

| Full text

November 2009 Br J Cardiol 2009;16:269-71

Clopidogrel needed for more than one year after drug-eluting stent placement?

BJCardio editorial staff

Abstract

These results, from the TYCOON (Two-Year Clopidogrel Need) registry, were published online on September 28, 2009 in the American Journal of Cardiology. Current guidelines recommend at least 9-12 months of dual antiplatelet therapy (aspirin plus clopidogrel) following intervention with a drug-eluting stent to prevent thromboses, but authors of the TYCOON paper, wanted to investigate whether longer treatment would be better. The TYCOON database includes 897 consecutive patients who received a coronary stent in 2003 and 2004, about half of whom received a drug-eluting stent. Patients given a drug-eluting stent in 2003 were treated with clopidog

| Full text

November 2009 Br J Cardiol 2009;16:281-6

Pharmaceutical salts: a formulation trick or a clinical conundrum?

Aateka Patel, Stuart A Jones, Albert Ferro, Nilesh Patel

Abstract

(more…)

| Full text

May 2009 Br J Cardiol 2009;16:121-125

News from the 58th Annual Scientific Session of the American College of Cardiology

BJCardio editorial staff

Abstract

Polypill could cut cardiovascular risk by half The strategy of giving a ‘polypill’, consisting of three antihypertensive drugs, a statin, and aspirin, to vast amounts of people who have not yet developed heart disease, could cut cardiovascular risk by half, according to the first major clinical trial of such an approach. The Indian Polycap Study (TIPS), presented at the ACC meeting by Dr Salim Yusuf (McMaster University, Hamilton, Ontario, Canada), included 2,053 patients aged 45–80 years without cardiovascular disease but with one risk factor (type 2 diabetes, high blood pressure, smoker within the past five years, increased waist-to-

| Full text

November 2008 Br J Cardiol 2008;15:307-11

South East London Cardiac Prescribing Forum: working to improve clopidogrel prescribing across the South East London sector

Helen Williams, Rachel Hughes, Lucy Simkins, Katie Hatton, Michael Currie, Holly Chong, Victoria Hill, Christopher Boddy, Sara Nelson, Claire Foreman on behalf of the Cardiac Prescribing Forum of the South East London Cardiac and Stroke Network (SELCSN)

Abstract

Introduction Over the past five years, clopidogrel, often in combination with aspirin, has become standard therapy for patients with a number of cardiovascular disorders. Dual therapy with aspirin and clopidogrel is particularly important in the management of ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and following intra-coronary stent placement. Evidence from clinical trials has demonstrated that the benefits of dual therapy are greatest where aspirin and clopidogrel are initiated early following an acute event or prior to a percutaneous coronary intervention (PCI). The optimal duration of clo

| Full text

July 2008 Br J Cardiol 2008;15:185-88

News

BJCardio editorial team

Abstract

New data on intensive glucose lowering in type 2 diabetes The results of three large trials investigating the clinical effects of intensive glucose lowering in patients with type II diabetes were presented at the recent American Diabetes Association meeting in San Francisco, USA, and have shown somewhat conflicting results. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was stopped earlier this year because of an increased mortality in the intensive glucose lowering group. The two other trials – ADVANCE (Action in Diabetes and Vascular Disease – Preterax and Diamicron MR Controlled Evaluation) and VADT (Veteran’s A

| Full text

September 2007 Br J Cardiol 2007;14:194-99

News from the 2007 Congress of the European Society of Cardiology

BJCardio editorial staff

Abstract

No content available

| Full text

July 2006 Br J Cardiol 2006;13:284-86

Should acute MI patients receive dual antiplatelet therapy: a review of new data

Anthony Gershlick

Abstract

No content available

| Full text

March 2006 Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 5–AIC 8

Bivalirudin, abciximab and clopidogrel in modern PCI: interpretation and experience from King’s College Hospital

Nick West

Abstract

No content available

| Full text

March 2006 Br J Cardiol 2006;13:90-8

American College of Cardiology 55th Annual Scientific Session

BJCardio editorial team

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now